BFRI vs. VYNE, CLDI, ATNM, IRD, GRCE, PASG, ANEB, CVKD, CALC, and IBIO
Should you be buying Biofrontera stock or one of its competitors? The main competitors of Biofrontera include VYNE Therapeutics (VYNE), Calidi Biotherapeutics (CLDI), Actinium Pharmaceuticals (ATNM), Opus Genetics (IRD), Grace Therapeutics (GRCE), Passage Bio (PASG), Anebulo Pharmaceuticals (ANEB), Cadrenal Therapeutics (CVKD), CalciMedica (CALC), and iBio (IBIO). These companies are all part of the "pharmaceutical products" industry.
Biofrontera vs.
Biofrontera (NASDAQ:BFRI) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, community ranking, profitability and analyst recommendations.
VYNE Therapeutics received 26 more outperform votes than Biofrontera when rated by MarketBeat users.
10.1% of Biofrontera shares are held by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are held by institutional investors. 0.2% of Biofrontera shares are held by company insiders. Comparatively, 4.8% of VYNE Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Biofrontera presently has a consensus target price of $7.00, indicating a potential upside of 530.63%. VYNE Therapeutics has a consensus target price of $6.88, indicating a potential upside of 150.91%. Given Biofrontera's higher probable upside, analysts plainly believe Biofrontera is more favorable than VYNE Therapeutics.
Biofrontera has higher revenue and earnings than VYNE Therapeutics. VYNE Therapeutics is trading at a lower price-to-earnings ratio than Biofrontera, indicating that it is currently the more affordable of the two stocks.
Biofrontera has a net margin of -36.31% compared to VYNE Therapeutics' net margin of -6,896.55%. VYNE Therapeutics' return on equity of -43.73% beat Biofrontera's return on equity.
Biofrontera has a beta of 0.29, indicating that its share price is 71% less volatile than the S&P 500. Comparatively, VYNE Therapeutics has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500.
In the previous week, VYNE Therapeutics had 6 more articles in the media than Biofrontera. MarketBeat recorded 7 mentions for VYNE Therapeutics and 1 mentions for Biofrontera. VYNE Therapeutics' average media sentiment score of 0.07 beat Biofrontera's score of 0.00 indicating that VYNE Therapeutics is being referred to more favorably in the news media.
Summary
VYNE Therapeutics beats Biofrontera on 11 of the 16 factors compared between the two stocks.
Get Biofrontera News Delivered to You Automatically
Sign up to receive the latest news and ratings for BFRI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biofrontera Competitors List
Related Companies and Tools
This page (NASDAQ:BFRI) was last updated on 2/22/2025 by MarketBeat.com Staff
Free BFRI Stock Alerts